Sillajen

Developer of oncolytic immunotherapeutics for the treatment of cancer

placeBusan, Busan, South Korea calendar_todayFounded 2006 groups49 employees language sillajen.com

Innovation

26 patent families (9 granted) — focus: Human necessities, Chemistry & metallurgy, Physics & computing; filing pace accelerating. Cited 1,289 times.

YearFilings
20152
20161
20174
20185
20196
20205
20214
20222
20236
202413
20257
20265

Investor mix

7 investors on record.

Investor typeCountShare
Venture capital686%
Private equity114%
Coming soon